Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)

Severe COVID-19 Clinical Trial

— IPCO  

Official title:

Randomized Controlled Phase 2b Clinical Study in Parallel Groups for the Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma Plus Standard Treatment vs. Standard Treatment Alone of Subjects With Severe COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04712344
• Other study ID #: UKER-COV2-01
• Status: Recruiting
• Phase: Phase 2
• Start date: January 18, 2021
• Est. completion date: September 2021

Study information

• Verified date: January 2021
• Source: University of Erlangen-Nürnberg Medical School
• Contact: Mario Schiffer, MD
• Phone: +49913185
• Email: mario.schiffer[@]uk-erlangen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 2b clinical study will enroll adult subjects of both sexes with ARDS due to COVID-19 necessitating invasive mechanical ventilation.

Description:

The primary objective of the study is the assessment of impact of immune therapy with COVID-19 convalescent plasma on severity of COVID-19.

The secondary objectives is the Impact of immune therapy with COVID-19 convalescent plasma on markers for ARDS due to severe COVID-19 infection; short-term all-cause mortality; time course of ARDS due to severe COVID-19 and assessment of safety and tolerability of immune therapy with COVID-19 convalescent plasma.

As a primary endpoint/variable we will assess change in SOFA score from Baseline Visit to Day 8.

The study design will be prospective, open-label, randomized, controlled and parallel-grouped.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: September 2021
• Est. primary completion date: September 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subject aged =18 years.

2. Estimated BMI =19kg/m² to =40kg/m².

3. Florid1 SARS-CoV-2 infection confirmed by RT-PCR in tracheo-bronchial secretion sample or pharyngeal swab sample.

4. ARDS with Horovitz index <300mmHg.

5. Necessity of invasive mechanical ventilation.

6. Written informed consent obtained from the subject's legal representative or under such arrangement as is legally acceptable in Germany (

7. Subject's assent if obtainable

Exclusion Criteria:

1. Previous exposure to COVID-19 convalescent plasma.

2. Adverse reaction to plasma proteins in medical history.

3. Interval >72h since endotracheal intubation.

4. Current or imminent necessity of ECMO treatment.

5. Pre-existing COPD GOLD stage 4.

6. Chronic congestive heart failure NYHA =3.

7. Pre-existing left ventricular ejection fraction <30%.

Related Conditions & MeSH terms

• Severe COVID-19

Intervention

Biological:
• COVID-19 convalescent plasma
Infusion of a total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 in Addition to standard treatment.

Locations

Country	Name	City	State
Germany	University Hospital Erlangen	Erlangen

Sponsors (1)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg Medical School

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in SOFA score from Baseline Visit	Change in Sequential organ failure assessment (SOFA) score predicts Predicts ICU mortality based on lab results and clinical data. SOFA includes PaO2, the Glasgow Coma Scale, Mean arterial pressure OR Administration of sedatives, Bilirubin(mg/dl), Creatinine (mg/dl) and platelets. All values are rated with a value of 1 to 4 (worst condition) and are added up gradually to a final score. The lower the SOFA score, the better is the prognosis (Maximum value 24)	[Day 1, Visit 2] to Day 8 [Visit 9]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on markers for ARDS due to severe COVID-19 infection	Mean number of days without invasive mechanical ventilation during the period from Baseline Visit [Day 1, Visit 2] until and including Day 8 [Visit 9], Day 15 [Visit 13], and Day 29 [Visit 15], per treatment group and per subject.; Time from Baseline Visit [Day 1, Visit 2] to extubation.	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on short-term all-cause mortality	Assessment of mortality during defined time-frame	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen supply in patients with ARDS due to severe COVID-19	Number of subjects without supplemental oxygen on Day 8 [Visit 9], on Day 15 [Visit 13], and on Day 29 [Visit 15].	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen demand in patients with ARDS due to severe COVID-19	Proportion of subjects without supplemental oxygen on Day 8 [Visit 9], on Day 15 [Visit 13], and on Day 29 [Visit 15].	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of Oxygen supply in patients with ARDS due to severe COVID-19	Mean number of days without supplemental oxygen during the period from Baseline Visit [Day 1, Visit 2] until and including Day 8 [Visit 9], Day 15 [Visit 13], and Day 29 [Visit 15], per treatment group and per subject.	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on PEEP in patients with ARDS due to severe COVID-19	Mean relative change of PEEP from Baseline Visit [Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15] or until stop of invasive mechanical ventilation, whichever comes first.	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on FiO2 in patients with ARDS due to severe COVID-19	Mean relative change of FiO2 from Baseline Visit [Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15] or until stop of invasive mechanical ventilation, whichever comes first.	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on driving pressure in patients with ARDS due to severe COVID-19	Mean relative change of driving pressure from Baseline Visit [Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15] or until stop of invasive mechanical ventilation, whichever comes first.	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]
Secondary	Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of invasive mechanical Ventilation in patients with ARDS due to severe COVID-19	Time from Baseline Visit [Day 1, Visit 2] to stop of invasive mechanical ventilation.	Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15]